IPSC Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
25.2M
-31.0%
36.5M
+54.2%
23.7M
+14.7%
20.7M
-42.8%
36.1M
R&D
18.1M
-7.8%
19.6M
+14.6%
17.1M
-13.2%
19.7M
-12.6%
22.5M
SG&A
7.1M
+23.5%
5.8M
-12.0%
6.6M
+588.2%
956.0K
-86.0%
6.8M
Operating Income
-25206000
+31.0%
-36527000
-54.2%
-23684000
-14.7%
-20651000
+42.8%
-36124000
EBITDA
-23021000
-1.1%
-22767000
-10.1%
-20680000
-20.9%
-17101000
+34.8%
-26232000
Net Income
-23453000
+32.1%
-34550000
-59.6%
-21645000
-12.9%
-19171000
+44.3%
-34422000
EPS (Basic)
$-0.11
+35.3%
$-0.17
-54.5%
$-0.11
+50.0%
$-0.22
+45.0%
$-0.40
EPS (Diluted)
$-0.11
+35.3%
$-0.17
-54.5%
$-0.11
+50.0%
$-0.22
+45.0%
$-0.40
Shares (Diluted)
206.4M
+0.3%
205.8M
+6.4%
193.5M
+121.3%
87.4M
+1.1%
86.5M
Century Therapeutics (IPSC) — Financials